Standard & Poor’s has raised the outlook on the “A+” rating of SCOR SE and its main subsidiaries to “positive” as, according to S&P’s statement, “capital and earnings expected to rise due to very strong ERM”.
Standard & Poor’s has raised the outlook on the “A+” rating of SCOR SE and its main subsidiaries to “positive” as, according to S&P’s statement, “capital and earnings expected to rise due to very strong ERM”.
SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million.
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
Winner of the Actuarial Award in Germany, 2013
Winner of the Actuarial Award in Germany, 2013
Winner of the Actuarial Award in Germany, 2013
SCOR's results for the first nine months of 2013.
SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million.
SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million.
